NCT03540823View on ClinicalTrials.gov

Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases

PHASE4CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

April 23, 2018

Primary Completion Date

June 23, 2018

Study Completion Date

August 23, 2018

Conditions
Systemic LupusSjogren's Syndrome
Interventions
BIOLOGICAL

Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus; B / Phuket / 3073/2013-like virus)

Single dose of Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus; B / Phuket / 3073/2013-like virus)

Trial Locations (1)

05403-000

Rheumatology Division of Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo, São Paulo

All Listed Sponsors
lead

University of Sao Paulo General Hospital

OTHER

NCT03540823 - Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases | Biotech Hunter | Biotech Hunter